GR3029716T3 - Respiratory syncytial virus (RSV) mutant and pharmaceutical composition containing such a mutant - Google Patents

Respiratory syncytial virus (RSV) mutant and pharmaceutical composition containing such a mutant

Info

Publication number
GR3029716T3
GR3029716T3 GR990400565T GR990400565T GR3029716T3 GR 3029716 T3 GR3029716 T3 GR 3029716T3 GR 990400565 T GR990400565 T GR 990400565T GR 990400565 T GR990400565 T GR 990400565T GR 3029716 T3 GR3029716 T3 GR 3029716T3
Authority
GR
Greece
Prior art keywords
mutant
rsv
pharmaceutical composition
composition containing
respiratory syncytial
Prior art date
Application number
GR990400565T
Other languages
English (en)
Inventor
Valerie Bruce Randolph
Joan Coflan Crowley
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of GR3029716T3 publication Critical patent/GR3029716T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR990400565T 1992-04-21 1999-03-18 Respiratory syncytial virus (RSV) mutant and pharmaceutical composition containing such a mutant GR3029716T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87142092A 1992-04-21 1992-04-21

Publications (1)

Publication Number Publication Date
GR3029716T3 true GR3029716T3 (en) 1999-06-30

Family

ID=25357402

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990400565T GR3029716T3 (en) 1992-04-21 1999-03-18 Respiratory syncytial virus (RSV) mutant and pharmaceutical composition containing such a mutant

Country Status (13)

Country Link
US (1) US5932222A (el)
EP (1) EP0567100B1 (el)
JP (1) JPH0622756A (el)
AT (1) ATE177785T1 (el)
AU (1) AU671983B2 (el)
CA (1) CA2094464C (el)
DE (1) DE69323921T2 (el)
DK (1) DK0567100T3 (el)
ES (1) ES2130189T3 (el)
GR (1) GR3029716T3 (el)
NZ (1) NZ247444A (el)
TW (1) TW275632B (el)
ZA (1) ZA932763B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0784486B1 (en) * 1994-10-05 2006-04-05 Vanderbilt University Interleukin-12 as an adjuvant for paramyxoviridae vaccines
US7846455B2 (en) * 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6689367B1 (en) * 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US6015664A (en) * 1995-11-03 2000-01-18 Mcw Research Foundation Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B
WO1997038138A1 (en) * 1996-04-04 1997-10-16 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
US6077514A (en) * 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
BR9712138A (pt) * 1996-09-27 2000-01-18 American Cyanamid Co Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
DE19729161A1 (de) 1997-07-08 1999-01-14 Basf Ag Thermisch härtbare, wässrige Zusammensetzungen
CN1273603A (zh) * 1997-09-19 2000-11-15 美国氰胺公司 减毒的呼吸道合胞病毒
AU767193B2 (en) * 1998-03-26 2003-11-06 Wyeth Holdings Corporation Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B
CA2418939A1 (en) * 2000-08-07 2002-02-14 Aventis Pasteur Limited Stabilization of immunogens derived from paramyxoviruses
BRPI0417672A (pt) * 2003-12-17 2007-03-20 Wyeth Corp processos para produzir composições de vìrus estáveis em armazenamento, composições de vìrus e imunogênicas
GB201202091D0 (en) 2012-02-07 2012-03-21 Renishaw Ireland Ltd Drug delivery apparatus
GB201202093D0 (en) * 2012-02-07 2012-03-21 Renishaw Ireland Ltd Drug storage apparatus
CN112501134B (zh) * 2020-12-09 2023-01-20 贵州医科大学附属医院 一种人呼吸道合胞病毒毒株及其应用
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3689622T2 (de) * 1986-01-14 1994-06-16 Univ North Carolina Impfstoffe gegen menschliche respiratorische viren.
US5149650A (en) * 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
AU2715288A (en) * 1987-11-20 1989-06-14 Upjohn Company, The Human respiratory syncytialvirus vaccine derived from the 1a (9.5 kd) protein
DE3878468T2 (de) * 1987-12-23 1993-06-09 Upjohn Co Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
IL105456A (en) * 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
AU3705793A (en) 1993-10-28
CA2094464C (en) 2005-08-23
AU671983B2 (en) 1996-09-19
CA2094464A1 (en) 1993-10-22
JPH0622756A (ja) 1994-02-01
ZA932763B (en) 1994-02-08
NZ247444A (en) 1994-12-22
US5932222A (en) 1999-08-03
TW275632B (el) 1996-05-11
DK0567100T3 (da) 1999-09-27
DE69323921D1 (de) 1999-04-22
EP0567100B1 (en) 1999-03-17
DE69323921T2 (de) 1999-08-26
ES2130189T3 (es) 1999-07-01
EP0567100A1 (en) 1993-10-27
ATE177785T1 (de) 1999-04-15

Similar Documents

Publication Publication Date Title
GR3029716T3 (en) Respiratory syncytial virus (RSV) mutant and pharmaceutical composition containing such a mutant
EP1347055A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
EP1071451A4 (en) COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS
AU2310995A (en) Peptide fragment of the respiratory syncytial virus protein g, immunogenic agent, pharmaceutical composition containing it and preparation process
EP2050464A3 (en) Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
HK1043943A1 (zh) 肺炎鏈球菌蛋白質和疫苗
CA2022420A1 (en) Escherichia coli vaccine
PL301576A1 (en) Novel hiv protease inhibitors, method of obtaining such inhibitors, pharmaceutical preparation and novel initial compounds
PL344851A1 (en) Bacterium of salmonella type and vaccine containing that bacterium for protecting animals against salmonellosis and method of obtaining such vaccine
WO1992006113A3 (en) Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant
HU9801705D0 (en) Streptococcus equi vaccine
AU653861B2 (en) Respiratory disease vaccine for cats
DK0626173T3 (da) Aerosolpræparat indeholdende fusafungin
DK0418990T3 (da) 13-brom- og 13,14-dibrom-ergoliner, deres fremstilling og anvendelse i lægemidler
IT8722791A0 (it) Attenuato cosi' ottenuto. procedimento per la preparazione di un ceppo mutante migliorato di bordetella bronchiseptica utile per un vaccino attenuato vivo per la protezione da infezioni di b.bronchiseptica e vaccino ar vivo